US Sen. Claire McCaskill is not done with Valeant Pharmaceuticals.
The company has been under pressure the past few weeks, first facing questions over drug pricing and then finding itself the focus of attention after short-seller Andrew Left published a report comparing it to Enron.
Valeant held an investor call Monday that was meant to address concerns over those allegations.
McCaskill, the top-ranking Democrat on the Senate’s Permanent Subcommittee on Investigations and the Senate Aging Committee, was not convinced by the call, however.
“The only thing that this morning’s investor call made clear is that Valeant’s questionable business practices extend well beyond price gouging,” McCaskillsaid in a statement.
Valeant said Monday that it would set up a committee to review business practices at Philidor, a specialty pharmacy it owns a stake in, which is at the center of fraud allegations.
Full content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
